Gilde Healthcare Partners invests in Symphogen A/S
31 January 2007
UTRECHT, The Netherlands, January 31, 2007 – Gilde Healthcare Partners today announced the investment of € 5 million by Gilde Healthcare II* in Symphogen A/S in an exclusive second closing of the series E round.
“We are pleased that Gilde, a well-respected global private equity company experienced with European life science companies, has demonstrated its belief in Symphogen’s recombinant polyclonal antibody technology through this investment,” said Kirsten Drejer, Ph.D, CEO of Symphogen. “This financing will be used to move our lead program, Sym001, into human clinical trials for prevention of Hemolytic Disease in Newborns (NHD) and for treatment of Idiopathic Thrombocytopenic Purpura (ITP), as well as to further advance additional Symphogen programs for vaccinia virus, anti-respiratory syncytial virus, and oncology.”
“Symphogen’s polyclonal antibody technology represents a totally new, innovative class of biopharmaceuticals and holds much promise to generate best-in-class therapies for treating serious human diseases. We followed Symphogen for some time and believe that the timing is right to invest, since company is on the verge of dosing its first human patients,” said Dirk Kersten, Investment Manager, of Gilde Healthcare Partners.
About Symphogen
Symphogen is the leader in developing recombinant polyclonal antibodies (pAb), a new class of biopharmaceuticals that capture the diversity and effectiveness of the natural immune system and can be used to treat a broad range of severe human diseases. Symphogen is building a proprietary product pipeline in infectious diseases and cancer and has established collaborations with international pharmaceutical companies.
Symphogen’s lead program, Sym001, in co-development with Biovitrum AB, will be the first recombinant polyclonal antibody to enter clinical evaluation in 2007 for NHD and ITP.
About Gilde Healthcare Partners
Gilde Healthcare Partners (Utrecht, The Netherlands) manages over EUR 200 million in venture funds focused on privately-held start-ups across the healthcare sector including (bio)pharmaceuticals, diagnostics, medical devices and enabling technologies.
The healthcare funds are managed by industry professionals with a balanced mix of operational and venture capital expertise. Gilde has the experience and resources to assist companies at any stage of development and provide support in M&A and public listing.
Contact Details: Dirk Kersten | +31 (0)30 2192536 | kersten@gilde.nl | www.gilde.nl
